Literature DB >> 16805708

Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations.

Ulrich Heininger1, James D Cherry.   

Abstract

Pertussis, or whooping cough, is an infectious disease that is caused by Bordetella pertussis, affects all age groups and is vaccine preventable. Recently, an increase in reported cases of pertussis in adolescents and adults has been noted in many countries despite high immunisation rates in children. Today pertussis outnumbers all other paediatric vaccine-preventable diseases in some countries. This observation can best be explained by an increased awareness of the disease, the availability of new diagnostic tests and, perhaps, suboptimal efficacy of some pertussis vaccines. In general, B. pertussis infections in adolescents and adults are of concern as they are the most important source of transmission of B. pertussis infections to young, unprotected infants. Many studies with diphtheria and tetanus toxoid, acellular pertussis component combination vaccines, specifically designed for use in adolescents and adults, have been performed and excellent tolerability and immunogenicity have been demonstrated. With the availability of two such products, booster doses in adolescents have been introduced in Canada, Austria, Australia, France, Germany and the US, and many other countries are considering similar expansion of their immunisation programmes at present. In addition, universal immunisation of adults (Austria, every 10 years) or targeting high risk groups (e.g., parents of newborns and other care-givers to children; Germany) have been recommended. If lifelong regular booster doses against pertussis were to be recommended and universal implementation was obtained, the authors believe that the morbidity of pertussis and its spread to infants can be dramatically reduced, and it is possible that the circulation of B. pertussis could be eliminated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16805708     DOI: 10.1517/14712598.6.7.685

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  5 in total

1.  The Swiss National Vaccination Coverage Survey, 2005-2007.

Authors:  Phung Lang; Hanspeter Zimmermann; Ursula Piller; Robert Steffen; Christoph Hatz
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

2.  Pertussis vaccine: a critique.

Authors:  John B Robbins; Rachel Schneerson; Jerry M Keith; Mark A Miller; Joanna Kubler-Kielb; Birger Trollfors
Journal:  Pediatr Infect Dis J       Date:  2009-03       Impact factor: 2.129

3.  Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study.

Authors:  C Conde-Glez; E Lazcano-Ponce; R Rojas; R DeAntonio; L Romano-Mazzotti; Y Cervantes; E Ortega-Barría
Journal:  Epidemiol Infect       Date:  2013-06-05       Impact factor: 4.434

4.  Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years.

Authors:  Nihal M Ibrahim; Ebtsam M El-Kady; Somiaa A Eissa; Ahmed F Wahby
Journal:  J Adv Res       Date:  2015-03-21       Impact factor: 10.479

5.  Epidemiology incidence and geographical distribution of Pertussis using GIS and its incidence prediction in Iran in 2021.

Authors:  Seyed Mohsen Zahraei; Parvin Mohamadi; Ghobad Moradi; Samira Shirzadi; Fatemeh Azimian; Zaher Khazaei; Hasan Naemi; Elham Goodarzi
Journal:  Med J Islam Repub Iran       Date:  2021-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.